JP2023022326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023022326A5 JP2023022326A5 JP2022197763A JP2022197763A JP2023022326A5 JP 2023022326 A5 JP2023022326 A5 JP 2023022326A5 JP 2022197763 A JP2022197763 A JP 2022197763A JP 2022197763 A JP2022197763 A JP 2022197763A JP 2023022326 A5 JP2023022326 A5 JP 2023022326A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- human
- seq
- nucleotide sequence
- encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 44
- 125000003729 nucleotide group Chemical group 0.000 claims 44
- 108700026244 Open Reading Frames Proteins 0.000 claims 42
- 108020004999 messenger RNA Proteins 0.000 claims 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 24
- 108010065637 Interleukin-23 Proteins 0.000 claims 21
- 102000013264 Interleukin-23 Human genes 0.000 claims 21
- 101000998124 Homo sapiens Interleukin-36 gamma Proteins 0.000 claims 16
- 102000055226 human IL36G Human genes 0.000 claims 16
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims 14
- 102000051450 human TNFSF4 Human genes 0.000 claims 14
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims 12
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims 12
- 150000002632 lipids Chemical class 0.000 claims 10
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims 9
- 229930182558 Sterol Natural products 0.000 claims 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 8
- 150000003904 phospholipids Chemical class 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 150000003432 sterols Chemical class 0.000 claims 8
- 235000003702 sterols Nutrition 0.000 claims 8
- 108091051828 miR-122 stem-loop Proteins 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 claims 4
- 108091066112 miR-122-1 stem-loop Proteins 0.000 claims 4
- 108091057488 miR-122-2 stem-loop Proteins 0.000 claims 4
- 108091070501 miRNA Proteins 0.000 claims 4
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 3
- 229940045145 uridine Drugs 0.000 claims 3
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical group O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 claims 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 2
- 108091007780 MiR-122 Proteins 0.000 claims 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 2
- -1 amino lipid Chemical class 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
Applications Claiming Priority (26)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338506P | 2016-05-18 | 2016-05-18 | |
| US201662338483P | 2016-05-18 | 2016-05-18 | |
| US201662338496P | 2016-05-18 | 2016-05-18 | |
| US201662338467P | 2016-05-18 | 2016-05-18 | |
| US62/338,483 | 2016-05-18 | ||
| US62/338,467 | 2016-05-18 | ||
| US62/338,496 | 2016-05-18 | ||
| US62/338,506 | 2016-05-18 | ||
| US201662404173P | 2016-10-04 | 2016-10-04 | |
| US201662404175P | 2016-10-04 | 2016-10-04 | |
| US62/404,173 | 2016-10-04 | ||
| US62/404,175 | 2016-10-04 | ||
| US201662415424P | 2016-10-31 | 2016-10-31 | |
| US62/415,424 | 2016-10-31 | ||
| US201662438945P | 2016-12-23 | 2016-12-23 | |
| US201662438942P | 2016-12-23 | 2016-12-23 | |
| US62/438,945 | 2016-12-23 | ||
| US62/438,942 | 2016-12-23 | ||
| US201762443693P | 2017-01-07 | 2017-01-07 | |
| US62/443,693 | 2017-01-07 | ||
| US201762472513P | 2017-03-16 | 2017-03-16 | |
| US62/472,513 | 2017-03-16 | ||
| US201762480400P | 2017-04-01 | 2017-04-01 | |
| US62/480,400 | 2017-04-01 | ||
| JP2018560868A JP7194594B2 (ja) | 2016-05-18 | 2017-05-18 | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
| PCT/US2017/033395 WO2017201325A1 (en) | 2016-05-18 | 2017-05-18 | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560868A Division JP7194594B2 (ja) | 2016-05-18 | 2017-05-18 | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023022326A JP2023022326A (ja) | 2023-02-14 |
| JP2023022326A5 true JP2023022326A5 (https=) | 2023-05-09 |
| JP7586883B2 JP7586883B2 (ja) | 2024-11-19 |
Family
ID=59009786
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560868A Active JP7194594B2 (ja) | 2016-05-18 | 2017-05-18 | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
| JP2022197763A Active JP7586883B2 (ja) | 2016-05-18 | 2022-12-12 | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560868A Active JP7194594B2 (ja) | 2016-05-18 | 2017-05-18 | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (10) | US10172808B2 (https=) |
| EP (2) | EP3458474B1 (https=) |
| JP (2) | JP7194594B2 (https=) |
| KR (2) | KR102482867B1 (https=) |
| CN (2) | CN116726203A (https=) |
| AU (2) | AU2017266929B2 (https=) |
| CA (1) | CA3024917A1 (https=) |
| DK (1) | DK3458474T3 (https=) |
| ES (1) | ES2932516T3 (https=) |
| HR (1) | HRP20221135T8 (https=) |
| HU (1) | HUE059955T2 (https=) |
| LT (1) | LT3458474T (https=) |
| MA (1) | MA45035B1 (https=) |
| PL (1) | PL3458474T3 (https=) |
| PT (1) | PT3458474T (https=) |
| RS (1) | RS63625B1 (https=) |
| SI (1) | SI3458474T1 (https=) |
| SM (1) | SMT202300003T1 (https=) |
| WO (1) | WO2017201325A1 (https=) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| PL3394093T3 (pl) | 2015-12-23 | 2022-05-16 | Modernatx, Inc. | Metody stosowania polinukleotydów kodujących ligand ox40 |
| JP7194594B2 (ja) | 2016-05-18 | 2022-12-22 | モデルナティエックス インコーポレイテッド | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
| JP2019519516A (ja) | 2016-05-18 | 2019-07-11 | モデルナティーエックス， インコーポレイテッド | がんの治療のためのｍＲＮＡ併用療法 |
| WO2017223176A1 (en) | 2016-06-24 | 2017-12-28 | Modernatx, Inc. | Methods and apparatus for filtration |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| EP4186888B1 (en) | 2017-03-15 | 2025-11-26 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2019067464A1 (en) * | 2017-09-27 | 2019-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | THERAPEUTIC AGENTS SPECIALLY ADMINISTERED BY EXOSOMES FOR THE TREATMENT OF CANCER |
| AU2018367452B2 (en) | 2017-11-14 | 2024-06-13 | Memorial Sloan-Kettering Cancer Center | IL-36 secreting immunoresponsive cells and uses thereof |
| EP3741861A4 (en) * | 2018-01-19 | 2021-12-08 | Cafa Therapeutics Limited | SYNNOTCH RECEPTOR REGULATED EXPRESSION OF IL12 |
| US20210061843A1 (en) * | 2018-01-22 | 2021-03-04 | Modernatx, Inc. | Multimeric polynucleotides and uses thereof |
| EP4008333A1 (en) * | 2018-02-19 | 2022-06-08 | Combined Therapeutics, Inc. | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| JP7556848B2 (ja) * | 2018-09-14 | 2024-09-26 | モデルナティエックス インコーポレイテッド | ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物 |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020097409A2 (en) * | 2018-11-08 | 2020-05-14 | Modernatx, Inc. | Use of mrna encoding ox40l to treat cancer in human patients |
| US12042527B2 (en) | 2019-01-08 | 2024-07-23 | Modernatx, Inc. | Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| US20240108747A1 (en) * | 2019-03-21 | 2024-04-04 | Lonza Sales Ag | Extracellular vesicle conjugates and uses thereof |
| WO2020198338A1 (en) * | 2019-03-25 | 2020-10-01 | Ohio State Innovation Foundation | Combination immunoregulation and uses thereof |
| CN114555191A (zh) * | 2019-05-29 | 2022-05-27 | 奥比思健康解决方案有限责任公司 | 用于表达嵌合受体的递送载体和颗粒及其使用方法 |
| MX2022000541A (es) | 2019-07-12 | 2022-04-18 | Univ Oregon Health & Science | Construcciones terapeuticas para la administracion conjunta de un inhibidor de la quinasa mitotica y un inhibidor de puntos de control inmunitario. |
| US20220249389A1 (en) | 2019-07-12 | 2022-08-11 | Oregon Health & Science University | Immunotherapeutic constructs and methods of their use |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| EP4031165A4 (en) * | 2019-09-20 | 2023-10-11 | University of Pittsburgh - Of the Commonwealth System of Higher Education | ONCOLYTIC VIRUSES EXPRESSING IL-36 CYTOKINE FOR THE TREATMENT OF CANCER |
| WO2021072172A1 (en) * | 2019-10-09 | 2021-04-15 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
| JP2022552378A (ja) | 2019-10-15 | 2022-12-15 | モデルナティエックス インコーポレイテッド | パーキンソン病を治療するための顆粒球マクロファージコロニー刺激因子をコードするｍＲＮＡ |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| WO2021204175A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticle composition |
| EP4132576A1 (en) | 2020-04-09 | 2023-02-15 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| WO2021231854A1 (en) | 2020-05-14 | 2021-11-18 | Modernatx, Inc. | Lnp compositions comprising an mrna therapeutic and an effector molecule |
| EP4157319A1 (en) * | 2020-05-28 | 2023-04-05 | Modernatx, Inc. | Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer |
| EP4168556A2 (en) | 2020-06-23 | 2023-04-26 | ModernaTX, Inc. | Lnp compositions comprising mrna therapeutics with extended half-life |
| US11611540B2 (en) * | 2020-07-01 | 2023-03-21 | Vmware, Inc. | Protection of authentication data of a server cluster |
| CN111931428B (zh) * | 2020-07-06 | 2023-06-20 | 武汉第二船舶设计研究所(中国船舶重工集团公司第七一九研究所) | 一种用于优化海洋核动力平台的方法及系统 |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN114073677B (zh) * | 2020-08-20 | 2023-06-09 | 深圳深信生物科技有限公司 | 一种脂质纳米颗粒 |
| CN112516378B (zh) * | 2020-12-02 | 2022-02-11 | 浙江工业大学 | 一种植酸/丝素蛋白/煅烧白云石骨粘合剂的制备方法 |
| WO2022120560A1 (zh) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用 |
| CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| WO2022174079A1 (en) | 2021-02-12 | 2022-08-18 | Modernatx, Inc. | Lnp compositions comprising payloads for in vivo therapy |
| US20240216288A1 (en) | 2021-03-24 | 2024-07-04 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| US20240207374A1 (en) | 2021-03-24 | 2024-06-27 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| US20240226025A1 (en) | 2021-03-24 | 2024-07-11 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| WO2022204370A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency |
| WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| AU2022291742A1 (en) * | 2021-06-14 | 2023-12-21 | Generation Bio Co. | Cationic lipids and compositions thereof |
| EP4355882A2 (en) | 2021-06-15 | 2024-04-24 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
| WO2022271776A1 (en) | 2021-06-22 | 2022-12-29 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| CN115611757A (zh) * | 2021-07-16 | 2023-01-17 | 江苏慧聚药业股份有限公司 | mRNA传递剂的合成 |
| CN115703713B (zh) * | 2021-08-13 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| US20240398940A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| WO2023056044A1 (en) | 2021-10-01 | 2023-04-06 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
| CN116829578B (zh) * | 2021-10-08 | 2025-03-21 | 苏州艾博生物科技有限公司 | 编码白细胞介素-12(il-12)的多核苷酸以及其相关组合物和方法 |
| CN114231624A (zh) * | 2021-10-28 | 2022-03-25 | 苏州大学附属第一医院 | 一种环状非编码rna在肾癌骨转移早期诊断及治疗中的应用 |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US20250041393A1 (en) | 2021-11-01 | 2025-02-06 | Modernatx, Inc. | Polynucleotides encoding integrin beta-6 and methods of use thereof |
| NL2030022B1 (en) | 2021-12-03 | 2023-06-21 | Wisdom Pharmaceutical Co Ltd | SYNTHESIS OF mRNA TRANSMITTER |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN115304756B (zh) * | 2022-01-30 | 2023-05-09 | 上海科技大学 | 一种五元脂质纳米颗粒及其制备方法和应用 |
| US20250213664A1 (en) | 2022-02-18 | 2025-07-03 | Modernatx, Inc. | Mrnas encoding checkpoint cancer vaccines and uses thereof |
| US20250221931A1 (en) | 2022-03-25 | 2025-07-10 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
| WO2023196399A1 (en) | 2022-04-06 | 2023-10-12 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2023246840A1 (en) * | 2022-06-22 | 2023-12-28 | Wuhan Houxian Biopharmaceutical Co. Ltd. | Combination of il-12 and ox40l for cancer immunotherapy |
| CA3261027A1 (en) * | 2022-07-10 | 2024-01-18 | Precigen, Inc. | POLYCISTRONIC miRNA CONSTRUCTS FOR IMMUNE CHECKPOINT INHIBITION |
| WO2024026254A1 (en) | 2022-07-26 | 2024-02-01 | Modernatx, Inc. | Engineered polynucleotides for temporal control of expression |
| IL319596A (en) * | 2022-09-22 | 2025-05-01 | Univ Texas | Novel secretory signal peptides |
| CN115869332A (zh) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | 递送至体内后在肝脏少表达的mRNA药物及其制备方法 |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
| CN115671045B (zh) * | 2022-12-30 | 2023-04-07 | 华南理工大学 | 非肝靶向的核酸纳米制剂及其制备方法和应用 |
| WO2024182301A2 (en) | 2023-02-27 | 2024-09-06 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024206329A1 (en) | 2023-03-27 | 2024-10-03 | Modernatx, Inc. | Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof |
| EP4704816A1 (en) | 2023-05-03 | 2026-03-11 | ModernaTX, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| CN119101681A (zh) * | 2023-06-09 | 2024-12-10 | 仁景(苏州)生物科技有限公司 | 表达可调控的工程化rna分子 |
| WO2025184429A1 (en) | 2024-02-28 | 2025-09-04 | Modernatx, Inc. | Bromodomain and extra-terminal domain (bet) epigenetic reader decoy |
| WO2025231407A1 (en) * | 2024-05-03 | 2025-11-06 | Nutech Ventures | Lipid nanoparticles and methods of making and using |
| WO2025255199A1 (en) | 2024-06-05 | 2025-12-11 | Modernatx, Inc. | Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof |
| WO2026025031A1 (en) | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Mrna encoding mageb2 tcer molecule |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
| US6140496A (en) | 1990-10-09 | 2000-10-31 | Benner; Steven Albert | Precursors for deoxyribonucleotides containing non-standard nucleosides |
| US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| AU3534199A (en) | 1998-04-23 | 1999-11-08 | Takara Shuzo Co., Ltd. | Method For Synthesizing DNA |
| AU6270499A (en) | 1998-09-29 | 2000-04-17 | Phylos, Inc. | Synthesis of codon randomized nucleic acids |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| ATE427992T1 (de) | 2001-11-14 | 2009-04-15 | Toyo Boseki | Dna-synthesepromotoren, mit dna-polymerase assoziierte faktoren und nutzung davon |
| CA2409775C (en) | 2001-12-03 | 2010-07-13 | F. Hoffmann-La Roche Ag | Reversibly modified thermostable enzymes for dna synthesis and amplification in vitro |
| EP1490494A1 (en) | 2002-04-01 | 2004-12-29 | Walter Reed Army Institute of Research | Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell |
| DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| US7550264B2 (en) | 2005-06-10 | 2009-06-23 | Datascope Investment Corporation | Methods and kits for sense RNA synthesis |
| CA2613442C (en) | 2005-06-30 | 2016-08-23 | Archemix Corp. | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts |
| US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US20080046192A1 (en) | 2006-08-16 | 2008-02-21 | Richard Lathrop | Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same |
| WO2008078180A2 (en) | 2006-12-22 | 2008-07-03 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CA2715078C (en) | 2007-09-26 | 2019-07-23 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
| KR101867606B1 (ko) * | 2007-11-07 | 2018-06-18 | 제넨테크, 인크. | 미생물 질환의 치료를 위한 조성물 및 방법 |
| SG10201408162PA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
| CA2721333C (en) * | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| EP2288336B8 (en) | 2008-04-25 | 2017-03-22 | Northwestern University | Nanostructures suitable for sequestering cholesterol |
| US7561973B1 (en) | 2008-07-31 | 2009-07-14 | Dna Twopointo, Inc. | Methods for determining properties that affect an expression property value of polynucleotides in an expression system |
| US8401798B2 (en) | 2008-06-06 | 2013-03-19 | Dna Twopointo, Inc. | Systems and methods for constructing frequency lookup tables for expression systems |
| US8126653B2 (en) | 2008-07-31 | 2012-02-28 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20110082055A1 (en) | 2009-09-18 | 2011-04-07 | Codexis, Inc. | Reduced codon mutagenesis |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| US20130183718A1 (en) | 2010-09-21 | 2013-07-18 | RibpxX GmbH | Method for Synthesizing RNA using DNA Template |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| EP2755986A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| EP2766035B1 (en) * | 2011-10-11 | 2018-03-28 | Universität Zürich Prorektorat MNW | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| EP3466443B1 (en) | 2012-02-14 | 2020-12-16 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| AU2013374345A1 (en) | 2013-01-17 | 2015-08-06 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| PL4023249T3 (pl) * | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| EP3137105A4 (en) * | 2014-04-30 | 2017-12-27 | President and Fellows of Harvard College | Combination vaccine devices and methods of killing cancer cells |
| CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| JP2019519516A (ja) | 2016-05-18 | 2019-07-11 | モデルナティーエックス， インコーポレイテッド | がんの治療のためのｍＲＮＡ併用療法 |
| JP7194594B2 (ja) * | 2016-05-18 | 2022-12-22 | モデルナティエックス インコーポレイテッド | 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用 |
| KR102019331B1 (ko) | 2017-07-05 | 2019-09-09 | 한국과학기술연구원 | 모노포스포릴 지질 ａ를 구성적으로 생산하는 세균, 및 이를 이용한 모노포스포릴 지질 ａ 생산 방법 |
-
2017
- 2017-05-18 JP JP2018560868A patent/JP7194594B2/ja active Active
- 2017-05-18 AU AU2017266929A patent/AU2017266929B2/en not_active Ceased
- 2017-05-18 SM SM20230003T patent/SMT202300003T1/it unknown
- 2017-05-18 MA MA45035A patent/MA45035B1/fr unknown
- 2017-05-18 LT LTEPPCT/US2017/033395T patent/LT3458474T/lt unknown
- 2017-05-18 EP EP17727999.9A patent/EP3458474B1/en active Active
- 2017-05-18 DK DK17727999.9T patent/DK3458474T3/da active
- 2017-05-18 ES ES17727999T patent/ES2932516T3/es active Active
- 2017-05-18 KR KR1020187036733A patent/KR102482867B1/ko active Active
- 2017-05-18 SI SI201731226T patent/SI3458474T1/sl unknown
- 2017-05-18 PT PT177279999T patent/PT3458474T/pt unknown
- 2017-05-18 HR HRP20221135TT patent/HRP20221135T8/hr unknown
- 2017-05-18 KR KR1020227045735A patent/KR20230008243A/ko not_active Ceased
- 2017-05-18 WO PCT/US2017/033395 patent/WO2017201325A1/en not_active Ceased
- 2017-05-18 HU HUE17727999A patent/HUE059955T2/hu unknown
- 2017-05-18 RS RS20220929A patent/RS63625B1/sr unknown
- 2017-05-18 CN CN202310702910.3A patent/CN116726203A/zh active Pending
- 2017-05-18 EP EP22181855.2A patent/EP4137509A1/en not_active Withdrawn
- 2017-05-18 PL PL17727999.9T patent/PL3458474T3/pl unknown
- 2017-05-18 CN CN201780044529.5A patent/CN109476718B/zh active Active
- 2017-05-18 CA CA3024917A patent/CA3024917A1/en active Pending
-
2018
- 2018-06-01 US US15/995,889 patent/US10172808B2/en active Active
- 2018-11-08 US US16/184,282 patent/US10322090B2/en active Active
- 2018-12-13 US US16/219,418 patent/US10322091B2/en active Active
- 2018-12-17 US US16/222,155 patent/US10406113B2/en active Active
- 2018-12-20 US US16/227,810 patent/US10285950B2/en active Active
-
2019
- 2019-08-16 US US16/543,102 patent/US11185510B2/en active Active
-
2020
- 2020-10-15 US US17/071,685 patent/US11071716B2/en active Active
-
2021
- 2021-06-21 US US17/352,904 patent/US11344504B1/en active Active
-
2022
- 2022-05-27 US US17/826,387 patent/US20230041964A1/en not_active Abandoned
- 2022-09-07 US US17/930,369 patent/US11596609B2/en active Active
- 2022-12-12 JP JP2022197763A patent/JP7586883B2/ja active Active
-
2023
- 2023-08-03 AU AU2023210606A patent/AU2023210606A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023022326A5 (https=) | ||
| JP2022501336A5 (https=) | ||
| JP2025063273A5 (https=) | ||
| JP2025063030A5 (https=) | ||
| ES2625905T3 (es) | Nanopartículas que comprenden antígenos y adyuvantes capaces de estimular linfocitos T cooperadores | |
| EP3100718B1 (en) | Improved compositions and methods for the delivery of nucleic acids | |
| JP2020536125A5 (https=) | ||
| JP2012097094A5 (https=) | ||
| JP2020520640A5 (https=) | ||
| JP2019516351A5 (https=) | ||
| JP5277439B2 (ja) | 核酸内包高分子ミセル複合体 | |
| CN115778904B (zh) | 一种用于体外转染和体内递送mRNA的制剂 | |
| JP2021524270A5 (https=) | ||
| JP2020505330A5 (https=) | ||
| JP2020511521A (ja) | ｉｎ ｖｉｖｏでの核酸発現のためのシステム及び方法 | |
| JP2023526059A5 (https=) | ||
| JP2004513075A5 (https=) | ||
| EP2950825B1 (en) | Functionalized dna dendrimers for gene delivery to cells | |
| JP2021517471A5 (https=) | ||
| CN116554125A (zh) | 一种阳离子脂质类似物、其组合物及应用 | |
| CN119074950A (zh) | 一种增强mRNA-LNP组织靶向递送的方法 | |
| AU2021252496A1 (en) | Carriers for efficient nucleic acid delivery | |
| JP2022548031A5 (https=) | ||
| AU2021350020A1 (en) | Systems and methods for expressing biomolecules in a subject | |
| JP2026507514A (ja) | 修飾されたシトシンを含むｄｎａ組成物 |